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Summary
 
We have analyzed the immune system in Stat5-deficient mice. Although Stat5a
 
2/2
 
 splenocytes
have a partial defect in anti-CD3-induced proliferation that can be overcome by high dose in-
terleukin (IL)-2, we now demonstrate that defective proliferation in Stat5b
 
2/2
 
 splenocytes can-
not be corrected by this treatment. Interestingly, this finding may be at least partially explained
by diminished expression of the IL-2 receptor 
 
b
 
 chain (IL-2R
 
b
 
), which is a component of the
receptors for both IL-2 and IL-15
 
, 
 
although other defects may also exist. Similar to the defect
in proliferation in activated splenocytes, freshly isolated splenocytes from Stat5b
 
2/2
 
 mice ex-
hibited greatly diminished proliferation in response to IL-2 and IL-15. This results from both a
decrease in the number and responsiveness of natural killer (NK) cells. Corresponding to the
diminished proliferation, basal as well as IL-2– and IL-15–mediated boosting of NK cytolytic
activity was also greatly diminished. These data indicate an essential nonredundant role for
Stat5b for potent NK cell–mediated proliferation and cytolytic activity.
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S
 
ignal transducers and activators of transcription
(STAT)
 
1
 
 proteins are cytosolic latent transcription fac-
tors that are rapidly activated after cellular exposure to in-
terferons, cytokines, or growth factors (1–3). A consider-
able amount of investigation has centered on the specificity
of the signals transduced by each of the seven mammalian
STAT proteins. For three of these STATs (Stat1, Stat4, and
Stat6), knockout mice reveal specific defects limited to the
immune system consistent with defective signaling in re-
sponse to interferons (4, 5), IL-12 (6, 7), or IL-4/IL-13 (8–
10), respectively. In contrast, Stat3 knockout mice exhibit
fetal lethality (11), a finding consistent with the activation
of Stat3 by many important cytokines, including but not
limited to the IL-6 family of cytokines (IL-6, IL-11, ciliary
neurotrophic factor, leukemia inhibitory factor, onco-
statin M, and cardiotrophin 1; reference 3).
Stat5 was discovered as a mammary gland factor induced
by prolactin (12). Subsequently, a number of studies re-
vealed the existence of two closely related Stat5-like pro-
teins with 
 
.
 
90% amino acid identity, now denoted as
Stat5a and Stat5b (13–17). The genes encoding Stat5a and
Stat5b are closely linked on human chromosome 17 (17)
and mouse chromosome 11 (18). Both Stat5a and Stat5b
are activated not only by prolactin but also by a very wide
range of other cytokines, including growth hormone,
erythropoietin, thrombopoietin, hematopoietic cytokines
(IL-3, GM-CSF, and IL-5), and cytokines more specific for
lymphocytes (IL-2, IL-7, IL-9, and IL-15; reference 3).
Despite their similarities, Stat5a and Stat5b differ in their
COOH-terminal transactivation domains (19), and rela-
tively specific actions have been attributed to Stat5a and
Stat5b. For example, mice lacking Stat5a exhibit defective
lactation with impaired lobuloalveolar proliferation of the
mammary epithelium during pregnancy, and reduced ex-
pression of whey acidic protein (20), indicative of defective
prolactin signaling. Mice lacking Stat5b exhibit a loss of
sexually dimorphic growth, which results from sex differ-
ences in the pattern of growth hormone secretion from the
pituitary (21). A recent study analyzing mice in which the
two Stat5 genes were deleted individually or together (by
retargeting Stat5a
 
1/2
 
 embryonic stem cells with a Stat5b
targeting construct) confirmed these findings and addition-
 
1
 
Abbreviation used in this paper:
 
 STAT, signal transducers and activators of
transcription.
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ally showed a greater defect in growth in mice lacking both
genes (22). Thus, Stat5a and Stat5b have distinctive roles but
appear also to have partially redundant roles (22). Interest-
ingly, the double knockout mice also exhibited a significant
decrease in expression of Stat3 (which results in fetal lethality
when expression is totally eliminated; reference 11), raising
the possibility that diminished Stat3 levels contributed to
some of the abnormalities in these mice, such as the dimin-
ished response of bone marrow cells to G-CSF (22).
In Stat5a
 
2/2
 
 mice, bone marrow–derived macrophages
exhibit defective GM-CSF–induced proliferation and gene
expression (23); moreover, these mice also exhibit several
immunological defects, including reduced expansion of T
cells in vivo (24). This latter defect is associated with di-
minished IL-2–mediated induction of the IL-2R
 
a
 
 chain,
although TCR-mediated IL-2R
 
a
 
 induction appears to be
relatively normal; thus, impaired IL-2 signaling is believed
to at least partially explain the defects in these mice.
We have now analyzed the immunological properties in
Stat5b
 
2/2
 
 
 
mice and shown that they have a modest de-
crease in both thymic and splenic cellularity. Moreover,
Stat5b
 
2/2 
 
splenocytes exhibit a marked decrease in IL-2–
mediated proliferation and a more moderate decrease in the
number of NK cells. Although Stat5a
 
2/2
 
 mice also exhibit
a partial decrease in the number of NK cells, only the
Stat5b
 
2/2
 
 mice have a dramatic defect in NK cell function.
The implications of these findings are discussed below.
 
Materials and Methods
 
Mice.
 
The Stat5a
 
2/2
 
 (20) and Stat5b
 
2/2
 
 
 
mice (21) have been
described. These mice were backcrossed with C57BL/6 once,
and then littermates were intercrossed for this study. All experi-
ments were performed under protocols approved by National In-
stitutes of Health Animal Use and Care Committee and followed
the National Institutes of Health guidelines “Using Animals in
Intramural Research.”
 
Flow Cytometric Analysis.
 
Single-cell suspensions from the
thymus and spleen were stained and analyzed using a FACSort
 
Ò
 
(Becton Dickinson, San Jose, CA) with CELLQuest software (Bec-
ton Dickinson). The following antibodies were purchased from
PharMingen (San Diego, CA): PE-conjugated anti–TCR-
 
a
 
/
 
b
 
(anti-TCR-
 
a/b
 
–PE; H57-597 to TCR-
 
b
 
); anti-TCR-
 
g/d
 
–FITC
(GL3); anti-CD3
 
e
 
–allophycocyanin (145-2C11); anti-CD4–FITC,
–PE, and –Cy-Chrome (RM4-5); anti-CD8–PE, –Cy-Chrome,
and –allophycocyanin (53-6.7); anti-IL-2R
 
a
 
 (CD25)-FITC (7D4);
anti-CD44–Cy-Chrome (IM7); anti-CD45R (B220)–PE (RA3-
6B2); anti-IL-2R
 
b
 
–FITC and –PE (TM-
 
b
 
1); anti-Pan-NK cells–
FITC (DX5); and anti-
 
g
 
c
 
–PE (4G3). In some experiments, dead
cells were excluded by staining with propidium iodide.
 
RNA Analysis.
 
To evaluate IL-2–induced IL-2R
 
a
 
 and IL-2R
 
b
 
mRNA expression in activated lymphocytes, fresh splenocytes were
stimulated in Falcon 3003 plates (Becton Dickinson) coated with
10 
 
m
 
g/ml
 
 
 
anti-CD3
 
e
 
 mAb (145-2C11) for 48 h, washed twice with
PBS, and then cultured with or without 2 nM recombinant hu-
man IL-2 (Hoffmann-La Roche, Nutley, NJ) for 10 h. RNA
was extracted using Trizol (GIBCO BRL, Gaithersburg, MD),
fractionated on a 0.8% formaldehyde/agarose gel, and transferred
to nylon membranes. Blots were hybridized with 1.2 kb IL-2R
 
a
 
,
1.7 kb IL-2R
 
b
 
 (24), or control probe (0.3 kb pHe7 cDNA; refer-
ence 25) labeled with 
 
32
 
P using the Prime-It Rmt Kit (Stratagene,
La Jolla, CA). To evaluate perforin mRNA expression, RNA was
extracted from fresh splenocytes or splenocytes cultured for 90 h
at 2 
 
3 
 
10
 
6
 
/ml in RPMI 1640 medium containing 10% fetal bo-
vine serum, 50 
 
m
 
M 2-ME, and either IL-2 (10 nM) or IL-15
(15.5 nM). The blot was sequentially hybridized with murine
perforin (26) and pHe7 probes.
 
Western Blotting.
 
Whole cell extracts (15 
 
m
 
g/sample) were
fractionated on 8% SDS polyacrylamide gels and transferred to
Immobilon-P membranes (Millipore, Bedford, MA). Blots were
processed as previously described (24). In brief, after blocking,
blots were incubated with antisera specific for Stat5a or Stat5b
(17), followed by the incubation with anti–rabbit IgG conjugated
with horseradish peroxidase (Nycomed Amersham, Little Chal-
font, Buckinghamshire, UK). Blots were washed and developed
with an enhanced chemiluminescent substrate (Pierce Chemical
Co., Rockford, IL). To examine Stat6 expression, anti-Stat6 anti-
body (Transduction Laboratories, Lexington, KY) was used.
 
Proliferation Assay.
 
Fresh splenocytes (2 
 
3 
 
10
 
5
 
 cells/well)
were cultured in RPMI 1640 medium containing 10% fetal bo-
vine serum, 2 mM 
 
l
 
-glutamine, and antibiotics with or without
2 nM IL-2 or 100 ng/ml (7.75 nM) IL-15 (Peprotech, Rocky
Hill, NJ) for 48 h and pulsed with 1 
 
m
 
Ci of [
 
3
 
H]thymidine (6.7
Ci/mmol, NEN, Boston, MA) for the last 12 h of culture. For
proliferation of anti-CD3-stimulated splenocytes, cells (10
 
5
 
/well)
were cultured for 24 h in the presence or absence of 1 nM IL-2
with a 1 
 
m
 
Ci [
 
3
 
H]thymidine pulse for the last 10 h. Because IL-4
alone cannot potently stimulate splenocytes, we stimulated sple-
nocytes with a combination of PMA (1 ng/ml) and murine IL-4
(1,000 U/ml) for 48 h and pulsed them with 1 
 
m
 
Ci of [
 
3
 
H]thymi-
dine for the last 12 h of culture in order to evaluate the ability of
IL-4 to induce proliferation in Stat5-deficient mice.
 
Cytotoxicity Assay.
 
51
 
Cr-release assays were performed by
standard methods in final volumes of 200 
 
m
 
l. YAC-1 (H-2A), an
NK-sensitive cell, was used to assess NK activity with effector/
target ratios of 100, 50, 25, and 12.5:1 and 40, 10, 2.5, and 0.6:1,
respectively. 10 nM IL-2 or 15.5 nM IL-15 were added to wells.
Data are expressed as lytic units (LU) in 10
 
7 
 
cells (1 LU corre-
sponds to the number of effector cells lysing 20% of the targets)
and obtained by fitting the titration curves to scale families of
curves, as previously described (27).
 
Results and Discussion
 
The majority of mice lacking Stat5a have normal levels
of Stat5b in thymus and spleen (24). Correspondingly,
Stat5b
 
2/2
 
 mice express relatively normal levels of Stat5a.
Thus, in both Stat5a
 
2/2
 
 
 
and Stat5b
 
2/2
 
 mice, the loss of ex-
pression of one Stat5 gene did not typically affect the ex-
pression of the other Stat5 gene in either thymus or spleen,
although occasional variations were seen (Fig. 1 
 
A
 
, refer-
ence 24, and data not shown). Furthermore, both Stat5a
 
2/2
 
(24) and Stat5b
 
2/2
 
 mice had normal levels of Stat3 (data
not shown).
We first analyzed lymphoid development in Stat5b
 
2/2
 
mice. In these mice, thymocyte numbers were modestly
diminished (
 
P
 
 
 
, 
 
0.01; Fig. 1 
 
B
 
). Flow cytometric analysis
of thymocytes from these mice revealed that all populations
were represented, with almost normal numbers of CD4
and CD8
 
 
 
single positive and CD4
 
1
 
CD8
 
1
 
 double positive
thymocytes (Fig. 1 
 
C
 
). However, among the double nega- 
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tive cells there was a moderate decrease in the percentage
of CD44
 
1
 
CD25
 
2
 
 
 
cells and increase in the percentage of
CD44
 
2
 
CD25
 
1
 
 cells (Fig. 1 
 
D
 
).
In the periphery, Stat5b
 
2/2
 
 
 
mice tended to have de-
creased numbers of splenocytes (
 
P
 
 
 
, 
 
0.001; Fig. 1 
 
E
 
), as is
observed in Stat5a
 
2/2
 
 mice (24). The T/B cell ratio was
slightly decreased (Fig. 1 
 
F
 
). Flow cytometric analysis re-
vealed diminished numbers of single positive splenocytes;
the number of CD4
 
2
 
CD8
 
1
 
 splenocytes was substantially
reduced, whereas the number of CD4
 
1
 
CD8
 
2
 
 
 
cells was at
most only slightly affected (Fig. 1 
 
G
 
). Interestingly, whereas
Stat5a
 
2/2
 
 mice have decreased numbers of TCR-
 
g/d
 
 cells
in the spleen (24), this was not the case for Stat5b
 
2/2
 
 mice
(Fig. 1 
 
H
 
).
We next evaluated immune function in the periphery in
Stat5b
 
2/2
 
 mice and found a defect in the responsiveness of
splenocytes to mitogenic stimulation. Previously, we had
found that Stat5a
 
2/2
 
 splenocytes exhibited a defect in IL-2–
induced proliferation of splenocytes that had been preacti-
vated for 48 h with anti-CD3. However, the diminished
proliferation in Stat5a2/2 splenocytes could be overcome
with high concentrations of IL-2 (24), suggesting that this
defect primarily related to impaired IL-2–mediated in-
duction of IL-2Ra (24), a protein that is required for for-
mation of high-affinity IL-2 receptors (28). In Stat5b2/2
splenocytes, we observed a similar defect in IL-2–induced
IL-2Ra expression, both at the protein (Fig. 2 A) and
mRNA (Fig. 2, B and C) levels. This defect in IL-2–
induced IL-2Ra expression seen in both Stat5a2/2 and
Stat5b2/2 mice can be explained by the presence of an IL-2
response element in the IL-2Ra gene that is dependent on
Stat5 proteins (29–31). However, in contrast to the ability
Figure 1. (A) Extracts from thymuses (lanes 1–3) or spleens (lanes 4–6) were isolated from wild-type mice (lanes 1, 4), Stat5a2/2 mice (lanes 2, 5), or
Stat5b2/2 mice (lanes 3, 6), and proteins were then separated by SDS-PAGE and Western blotted with antisera specific for Stat5a (top) or Stat5b (bottom).
(B) Diminished thymocyte numbers in Stat5b2/2mice (7–10-wk-old mice were analyzed). (C and D) Flow cytometric analysis of thymocytes from 8-wk-
old mice. (C) CD4 versus CD8 flow cytometric profiles. (D) CD25 versus CD44 flow cytometric profiles of double negative thymocytes. (E) Diminished
numbers of splenocytes in Stat5b2/2 mice (7–10-wk-old mice were analyzed). (F–H) Flow cytometric profiles (8-wk-old mice) show a decrease in the ra-
tio of CD31 to B2201 cells (F) and a decrease in the percentage of CD81 single positive T cells (G) in Stat5b2/2 mice. The percentage of TCR-a/b and
TCR-g/d cells was normal in Stat5b2/2 mice (H).2070 Defective NK Function in Stat5b-deficient Mice
of high doses of IL-2 (sufficient to titrate intermediate af-
finity receptors) to normalize proliferation in Stat5a2/2
mice (reference 24 and data not shown), this was not the
case for Stat5b2/2 mice (Fig. 2 D). The diminished expres-
sion of IL-2Rb (Fig. 2, B and C) presumably contributed
to this effect. Thus, although diminished proliferation in
Stat5a2/2 mice is primarily related to diminished IL-2Ra
expression (24), the Stat5b2/2 mice appeared to have a
more defective IL-2-signaling pathway involving but not
necessarily limited to defective IL-2Ra and IL-2Rb ex-
pression. Indeed, additional defects are indicated given that
the Stat5b2/2 splenocytes also exhibited defective prolifera-
tion to a combination of PMA and IL-4 (Fig. 2 E), even
though IL-4 activates Stat6 rather than Stat5 proteins. Be-
cause Stat62/2 mice exhibit diminished IL-4–dependent
proliferation (8–10), we confirmed that Stat6 expression
was normal in Stat5b2/2 splenocytes (Fig. 2 F). These data
are consistent with a more general defect or perhaps multi-
ple defects that together diminish but not abrogate T cell
proliferation.
Considering the above partial defect in proliferation of
preactivated T cells, we next tested the ability of freshly iso-
lated splenocytes to proliferate in response to IL-2 and IL-
15. Proliferation of Stat5a2/2  splenocytes was at most
slightly diminished, whereas IL-2– and IL-15–induced pro-
liferation of Stat5b2/2 splenocytes was greatly diminished
(Fig. 3 A). We speculated that this defect in proliferation
might result from a decrease in the number and/or func-
tion of NK cells, given that NK cells represent a prominent
IL-2–responsive cell population in murine spleens and that
Figure 2. (A) Diminished IL-2–induced IL-2Ra expression in both CD41 and CD81 subpopulations of T cells after their preactivation with anti-
CD3. Fresh splenocytes were stimulated in Falcon 3003 plates coated with 10 mg/ml anti-CD3e mAb for 48 h, washed twice with PBS, and then cul-
tured with or without 2 nM IL-2 for 48 h. Cells were stained with anti-CD25–FITC, anti-CD4–PE, and anti-CD8–Cy-Chrome. Shown are IL-2Ra
expression and mean fluorescent intensity on CD41 or CD81 T cells from one representative mouse out of eight mice analyzed. (B) Northern blotting
for IL-2Ra, IL-2Rb, or control pHe7 using RNA from preactivated splenocytes not treated or treated with IL-2. Shown are representative data from
three mice. (C) The relative levels of IL-2Ra and IL-2Rb mRNA expression in B were normalized for pHe7 expression. (D) High dose IL-2 (1 nM)
could not restore proliferation of Stat5b2/2 splenocytes preactivated with anti-CD3. Shown are the mean 6 SEM from a compilation of two indepen-
dent experiments. (E) Proliferation to PMA plus IL-4 was done in Stat5b2/2 splenocytes. Shown are the mean 6 SD from a compilation of two experi-
ments. In one experiment, we confirmed that treatment of cells with PMA alone or IL-4 alone yielded minimal proliferation even in wild type mice. (F)
Equivalent expression of Stat6 in splenocytes from wild-type, Stat5a2/2 and Stat5b2/2 mice.2071 Imada et al.
IL-22/2 mice exhibit essentially normal T and B cell re-
sponses but compromised NK cell responses (32). Indeed,
flow cytometric analysis revealed that the percentage of
NK (CD32DX51) cells was uniformly diminished in
Stat5b2/2 mice (z55% of the percentage seen in wild-type
mice; Fig. 3 B). Interestingly, the percentage of NK cells in
Stat5a2/2 mice was also diminished, although to a lesser ex-
tent (z70% of the percentage seen in wild-type mice).
However, the much greater defect in proliferation in
Stat5b2/2 compared with Stat5a2/2 mice indicated that the
defect was not proportional to the number of NK cells but
rather reflected a greater functional defect in Stat5b2/2
mice.
Corresponding to the greater defect in proliferation in
freshly isolated splenocytes from Stat5b2/2 versus Stat5a2/2
mice (Fig. 3 A), NK cytolytic activity was much more im-
paired in Stat5b2/2 than in Stat5a2/2 splenocytes (Fig. 3 C).
The defect in Stat5b2/2 mice was even more evident when
either IL-2 (Fig. 3 D) or IL-15 (Fig. 3 E) was added during
the NK assay (note the difference in the scale on the ordi-
nate in Fig. 3, C–E). Thus, Stat5b2/2 mice exhibited sub-
stantial defects in both proliferative and cytolytic activities.
Because of these IL-2 and IL-15 signaling defects, and
because the IL-2 and IL-15 receptors both contain IL-2Rb
and gc as critical receptor components (33, 34), we evalu-
ated expression of these proteins in NK cells. No defect in
gc expression was observed in either Stat5a2/2 or Stat5b2/2
mice (data not shown). Interestingly, however, the number
of NK cells expressing IL-2Rb expression was uniformly
decreased in all Stat5b2/2 mice examined (n 5 17; Fig. 3 F);
in contrast, in Stat5a2/2 NK cells, IL-2Rb expression was
typically normal, although 2 out of 14 mice examined had
a significantly diminished percentage of IL-2Rb–express-
ing NK cells. Overall, the decreased number of IL-2Rb1
NK cells in Stat5b2/2 mice generally correlated with the
decreased proliferative response to IL-2 and IL-15 (Fig. 3 A)
as well as the marked decrease in IL-2– and IL-15–medi-
ated boosting of NK cytolytic activity (Fig. 3, D and E).
Again, however, the defects in IL-2– and IL-15–induced
proliferation and cytolytic activity were more severe than
would have been predicted based solely on the decreased
number of CD32DX51IL-2Rb1 cells, suggesting that
Stat5b plays an additional important and specific role(s) in
IL-2– and IL-15–induced signaling in NK cells.
To further investigate the basis for defective NK func-
tion, we examined b2-integrin (CD18) and perforin ex-
pression. CD18 is known to be important for recognition
of target cells by NK cells (35), and perforin is known to be
one of the key molecules for NK cell–mediated cytolysis
(36). Interestingly, although cell surface CD18 expression
was not diminished (data not shown), induction of perforin
mRNA by IL-2 and IL-15 was markedly decreased in
Stat5b2/2 splenocytes (Fig. 4).
The mechanism of NK cell development has been an
area of active investigation. NK cells do not develop in sev-
eral different knockout mice, including those lacking IL-
Figure 3. (A) Diminished proliferation of freshly isolated splenocytes
from Stat5b2/2 mice to 2 nM IL-2 or 7.75 nM IL-15. Shown are the
mean 6 SD from a compilation of two independent experiments. (B)
Flow cytometric analysis of CD32DX51 NK cells in splenocytes from
wild type, Stat5a2/2, and Stat5b2/2 mice. (C–E) Decreased NK cytolytic
activity in Stat5b2/2 mice in the presence of no cytokine (C), IL-2 (D), or
IL-15 (E). Shown are the mean 6 SEM from combining two or three in-
dependent experiments, each of which had three mice of each genotype.
(F) Defective IL-2Rb expression in NK cells in Stat5b2/2 mice, as com-
pared with levels in wild type or Stat5a2/2 mice. A total of 14 Stat5a2/2
and 17 Stat5b2/2 mice were examined.
Figure 4. (A) Northern blotting for perforin or control pHe7 using
RNA from fresh splenocytes or from splenocytes treated with IL-2 or IL-
15 for 90 h. (B) For each condition, the relative level of perforin mRNA
expression in A was normalized for pHe7 expression.2072 Defective NK Function in Stat5b-deficient Mice
2Rb (37), gc (38, 39), or Jak3 (40–42), which are receptor
or signaling components for both IL-2 and IL-15. Interest-
ingly, although IL-2 potently augments NK cytolytic activ-
ity, the fact that IL-22/2 mice have NK cells indicates that
IL-2 is not absolutely required for NK cell development.
Instead, IL-15 has been implicated as playing an important
role in NK cell development (43–46). Supporting this con-
cept, the absence of NK cells in IRF12/2 mice has been
correlated with defective IL-15 production (47). Our data
now reveal a partial decrease in NK cells in both Stat5a2/2
and Stat5b2/2 mice, indicating that Stat5 activation is vital
for normal NK cell development.
Interestingly, although diminished NK cells were seen in
both Stat5a2/2 and Stat5b2/2 mice, it was only the NK cells
from Stat5b2/2 mice that exhibited a dramatic defect in
their ability to respond to IL-2 and IL-15 (Fig. 3, D and E),
and only Stat5b2/2 mice that had a lower percentage of
NK cells expressing IL-2Rb (Fig. 3 F). The basis for this
decrease in IL-2Rb1 NK cells remains unclear; although a
number of transcription factors including early growth re-
sponse (Egr)-1, Ets-1, and GABP have been shown to be
important for IL-2Rb promoter activity (48, 49), a Stat5b-
dependent response element for this gene has not been
reported. The decrease in perforin mRNA in IL-2– and
IL-15–treated Stat5b2/2 splenocytes is consistent with per-
forin being a Stat5b-regulated gene.
In conclusion, just as Stat4 and Stat6, respectively, are
important for normal Th1 and Th2 cell development and
function (6–10), our results reveal that both Stat5a and
Stat5b contribute to normal NK cell development with a
greater defect being seen particularly for NK function in
Stat5b2/2 mice. Although Stat5a and Stat5b have similar
(but not identical) binding activities in vitro and can both
drive expression of similar reporter constructs in transfected
cells, the data presented here are consistent with published
studies suggesting differential roles for these proteins in
nonlymphoid settings in vivo (20–22). It will be vital to
further clarify the range of target genes that are controlled
by Stat5a and Stat5b. We have shown that IL-2Ra is defec-
tive in the absence of either Stat5 protein, whereas IL-2Rb
and perforin appear more dependent on Stat5b. Moreover,
by demonstrating that Stat5b plays a particularly critical role
for proliferation and cytolytic activity of NK cells, we now
provide a key example of different biological roles for these
two Stat5 proteins within the immune system.
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